Safety and Efficacy of Ropeginterferon Alfa-2b in Combination With Ruxolitinib in Patients With Myelofibrosis Demonstrating Suboptimal Response to Ruxolitinib Monotherapy

In this open-label single arm phase 2 study, approximately 20 patients with MF demonstrating suboptimal response to ruxolitinib monotherapy will be enrolled. Patients will continue to receive ruxolitinib at a stable dose and ropeginterferon alfa 2b will be added to the regimen.

Start Date01 Jan 2025

Sponsor / Collaborator

The University of Hong Kong

NCT06290765

/ Not yet recruitingPhase 4

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera - A Randomized Open Label Global Multicenter Study (PARADIGM-PV)

This is a randomized, open-label, multicenter, two-arm study to assess the efficacy and safety of ropeginterferon alfa-2b for patients with PV. The entire study period is 60 weeks, including a main treatment phase (32 weeks), an extension treatment phase (24 weeks), and a safety follow-up phase (four weeks). However, the study may be extended for additional period of treatment after Week 60 pending the primary endpoint analysis at Week 32. Approximately 70 patients with PV will be enrolled.

Start Date01 Jan 2025

Sponsor / Collaborator

PharmaEssentia Corp.

NCT06468033

/ Not yet recruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus

This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk.
Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.

Start Date01 Dec 2024

Sponsor / Collaborator

PharmaEssentia Corp.

100 Clinical Results associated with Ropeginterferon alfa-2b-NJFT

100 Translational Medicine associated with Ropeginterferon alfa-2b-NJFT

100 Patents (Medical) associated with Ropeginterferon alfa-2b-NJFT

255

Literatures (Medical) associated with Ropeginterferon alfa-2b-NJFT

01 Jun 2025·Pharmacology Research & Perspectives

Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera

Article

Author: Wu, Lei ; Suo, Shanshan ; Shen, Weihong ; Komatsu, Norio ; Sato, Toshiaki ; Shimoda, Kazuya ; Li, Yaning ; Liao, Jason ; Chen, Haoqi ; Su, Xia ; Zhang, Lei ; Fu, Rongfeng ; Wu, Daoxiang ; Jin, Jie ; Kirito, Keita ; Gao, Yucheng ; Qin, Albert ; Wang, Wei ; Zhang, Jingjing

ABSTRACT:

Ropeginterferon alfa‐2b (ropeg) represents a new‐generation interferon‐based therapy approved for polycythaemia vera (PV) treatment. This study aimed to elucidate its population pharmacokinetics‐pharmacodynamics (PopPK‐PD) and exposure‐response (E‐R) relationships. A PopPK model was developed using pooled data from four clinical studies, including two Phase I studies in healthy volunteers (n = 48) and two Phase II studies in Chinese or Japanese patients with PV (n = 78). Sequential modeling was used to analyze pharmacokinetics‐pharmacodynamics (PK‐PD) regarding hematological parameters, including hematocrit, platelet, and white blood cell counts. Hematological changes were simulated using fast‐ and slow‐dose titration regimens. Individual exposure values were used to analyze the E‐R relationships regarding complete hematologic response (CHR), driver mutation, JAK2V617F allele burden, and safety. In this study, we developed a target‐mediated drug disposition model. Sigmoid indirect effects elucidated the PK‐PD in terms of hematological changes. Simulations showed that the fast‐titration regimen significantly accelerated hematocrit reduction. Logistic regression models showed that the probability of achieving CHR increased with exposure at Week 24 but not at Week 52. In contrast, JAK2V617F allele reductions correlated with exposure at both Weeks 24 and 52. Exposure‐safety analysis revealed a manageable risk of adverse events associated with transaminase increases. This study established a robust framework for ropeg PK‐PD, providing insights into its E‐R relationships and disease‐modifying action.Trial Registration: A17‐102, A19‐201, and A20‐202 are registered at ClinicalTrials.gov. The registration numbers are as follows: A17‐102, NCT03546465; A19‐201, NCT04182100; and A20‐202, NCT05485948. A17‐101 is registered at www.chinadrugtrials.org.cn. The registration number is CTR20190451

01 May 2025·HemaSphere

Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)

Letter

Author: Illes, Arpad ; Empson, Victoria ; Krochmalczyk, Dorota ; Dulicek, Petr ; Egyed, Miklos ; Hasselbalch, Hans C. ; Gercheva‐Kyuchukova, Liana ; Sivcheva, Lylia ; Kiladjian, Jean‐Jacques ; Gisslinger, Heinz ; Kralovics, Robert ; Klade, Christoph ; Georgiev, Pencho ; Pylypenko, Halyna ; Krejcy, Kurt ; Mayer, Jiří ; Yablokova, Vera

01 May 2025·Therapeutic Advances in Hematology

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa—case report, review of the literature and multidisciplinary clinical practice recommendations

Article

Author: Zeerleder, Sacha S. ; Odermatt, Urs ; de Gottardi, Andrea ; Brand, Christoph ; Fischli, Stefan ; Melzer, Ralph ; Wuillemin, Walter A. ; Rüfer, Axel

Pegylated interferons alfa are increasingly used in patients with myeloproliferative neoplasms (MPN) due to their potential disease-modifying effect. Ropeginterferon alfa-2b has been approved for patients with polycythemia vera (PV) with no symptomatic splenomegaly as first-line cytoreductive therapy, based on the results of the PROUD-PV/CONTINUATION-PV studies, documenting significantly higher rates of complete hematologic response (CHR) compared with hydroxyurea from 2-year timepoint onward. Although safety profile of pegylated interferons is overall good, interferon-related toxicities can occur. Focus of this article is on interferon-mediated autoimmune diseases. We describe two patients with PV treated with pegylated interferons alfa, one patient developed a cutaneous, paranasal sarcoidosis without any systemic symptoms and was successfully treated with topical steroids. The other patient developed widespread psoriatric skin lesions, which were treated with moderate effect with topical therapy with calcipotriene and betamethasone dipropionate foam, antidry calm lotion and in the course of the disease with ultraviolet light therapy (UVB). Only with methotrexate she achieved a nearly complete remission of the psoriasis. In both patients pegylated interferon was continued in view of the CHR and therefore the beneficial effect on MPN. We review the pertinent literature on the management of interferon-mediated autoimmune diseases in patients with MPN. As there is little published evidence on that topic, we propose multidisciplinary clinical practice recommendations based on available evidence and clinical experience in the management of patients with MPN treated with pegylated interferon alfa.

News (Medical) associated with Ropeginterferon alfa-2b-NJFT

20 May 2025

·www.businesswire.com

PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will present results from the Phase 3 SURPASS-ET clinical trial in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. SURPASS-ET (NCT04285086) is evaluating ropeginterferon alfa-2b-njft as a second-line treatment for patients with essential thrombocythemia (ET). Earlier this year, PharmaEssentia announced positive topline Phase 3 results, with ropeginterferon alfa-2b-njft demonstrating a significantly higher durable clinical response rate compared to anagrelide (42.9% vs. 6.0%; p=0.0001), along with a favorable safety profile and a greater reduction in JAK2 V617F allelic burden over 12 months. Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi® for the treatment of adults with polycythemia vera (PV). BESREMi® has been recognized by the National Comprehensive Cancer Network® (NCCN®) as a preferred first-line cytoreductive therapy for adults with symptomatic, low-risk PV and the only preferred therapeutic option for both high-risk and low-risk (symptomatic) patients, regardless of treatment history. “Current options for patients with ET are limited. Standard therapies like hydroxyurea have notable drawbacks and do not target the underlying biology of the disease, while anagrelide has been associated with toxicity concerns and limited efficacy,” said Ruben Mesa, M.D., co-principal investigator, presenting author, and President of Atrium Health Levine Cancer Institute, the largest cancer program in the Carolinas which includes the Comprehensive Cancer Center at Wake Forest Baptist. “This marks the first registrational Phase 3 trial of a long-acting interferon in ET, demonstrating not only well-tolerated blood count control but also a measurable reduction in JAK2 mutation allele burden. These findings support further investigation of ropeginterferon as a second-line option for patients with ET who are seeking additional treatment approaches.” “The ASCO meeting is an important opportunity to share detailed findings of our positive data from the SURPASS-ET study with the medical community,” said Albert Qin, M.D., Ph.D., Chief Medical Officer of PharmaEssentia USA. “These data highlight a significant advance in the treatment of essential thrombocythemia and reinforce our commitment to delivering innovative, non-chemotherapy options for patients living with myeloproliferative neoplasms.“ Presentation Details Title: Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial Abstract Number: 6500 Presenter: Dr. Ruben Mesa Session: Hematologic Malignancies — Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: Monday, June 2, 2025 Time: 3:00 p.m. - 6:00 p.m. CDT About Essential Thrombocythemia Essential thrombocythemia is a chronic, rare blood disorder that is the most common type of myeloproliferative neoplasm. Essential thrombocythemia is most often caused by genetic mutations that cause the bone marrow to produce too many platelets, which can obstruct blood flow and cause a stroke, heart attack or pulmonary embolism. About BESREMi® (ropeginterferon alfa-2b-njft) in polycythemia vera (PV) BESREMi is an innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks (or every four weeks with hematological stability for at least one year), allowing flexible dosing that helps meet the individual needs of patients. BESREMi has orphan drug designation for the treatment of polycythemia vera (PV) in adults in the United States. BESREMi has been approved in more than 40 countries, with approval from the European Medicines Agency (EMA) in 2019, by the US Food and Drug Administration (FDA) in 2021, and by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan in 2023. It was invented by PharmaEssentia and is manufactured in the company’s Taichung plant, which was cGMP certified by TFDA in 2017 and by EMA in January 2018. PharmaEssentia retains full global intellectual property rights for the product in all indications. BESREMi was approved with a boxed warning for risk of serious disorders including aggravation of neuropsychiatric, autoimmune, ischemic and infectious disorders. Please see full Prescribing Information, including Boxed Warning. About PharmaEssentia PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. For more information about PharmaEssentia USA, visit the website, LinkedIn or X (formerly Twitter).

Drug ApprovalPhase 3Clinical ResultOrphan DrugASCO

20 Mar 2025

·www.businesswire.com

Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow. This results in a persistent increase in red blood cells, white blood cells, and platelets. PV can lead to cardiovascular complications such as thrombosis and embolism, and in a significant number of patients it can progress to secondary myelofibrosis or leukemia. The global incidence of PV is estimated at approximately 2.8 cases per 100,000 people per year. In Brazil, between 2016 and 2020, DataSUS recorded 1,843 cases of Polycythemia Vera, representing an incidence of 0.16 per 100,000 inhabitants. Despite being a rare disease, these numbers suggest the possibility of underdiagnosis and underreporting, highlighting a challenge in identifying affected patients. According to Fernanda Bertasi, General Manager of Pint Pharma in Brazil, "ANVISA’s approval of BESREMi® represents a transformative milestone for patients with Polycythemia Vera in Brazil. This new therapeutic option brings real hope, offering innovation and progress in disease treatment. This is an essential step in providing better health and well-being for these patients." Valnei Canutti, Hematologist and Chief Scientific Officer at Pint Pharma, emphasized that "BESREMi® is an innovative, monopegylated interferon with extended action due to its unique pharmacokinetic properties. Its approval was based on robust evidence from the PEGINVERA clinical study, which demonstrated superior and more sustained hematologic and clinical responses compared to standard therapy." For David Ricardo Muñoz Guzmán, CEO of Pint Pharma, "This therapeutic advancement reaffirms Pint Pharma’s commitment to being a community-centered company. Our mission goes beyond innovation and high technology, focusing on solutions that truly impact patients' lives by expanding access to treatments and improving healthcare quality." Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia, added, "The approval of BESREMi® by ANVISA is a testament to the power of strong cross-border partnerships in advancing healthcare and reinforces our mission to transform care for PV patients worldwide. We deeply appreciate the collaboration with the Pint Pharma team, whose expertise and dedication have been instrumental in bringing BESREMi® to patients in Brazil." BESREMi® is exclusively registered, marketed, and distributed by Pint Pharma in Brazil. About BESREMi® (ropeginterferon alfa-2b) in Polycythemia Vera (PV) BESREMi® is an innovative, monopegylated, long-acting interferon that has marketing authorization in over 40 countries, with approval from the European Medicines Agency (EMA) in 2019, the U.S. Food and Drug Administration (FDA) in 2021, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan in 2023.. With its exclusive pegylation technology, BESREMi® offers extended activity in the body and is designed for administration once every two weeks (or once every four weeks if hematologic stability is maintained for at least 1.5 years), allowing for flexible dosing tailored to individual patient needs. About PharmaEssentia PharmaEssentia Corporation (TWSE: 6446) headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. About Pint Pharma Pint Pharma is a biopharmaceutical company that specialises in the commercialisation of innovative therapies with the potential to transform outcomes in rare disease and other patient communities across the Latin American region. By collaborating with world-class biotech and pharma companies, Pint Pharma is committed to improving the lives of Latin American patients in areas of significant unmet medical need. The company is headquartered in Europe and counts with over 250 employees across its territories in Latin America including Brazil, Mexico, Argentina, Colombia, Chile, Peru and Ecuador. Pint Pharma licensed from PharmaEssentia the rights to commercialize BESREMi® in Brazil.

Drug Approval

20 Mar 2025

·www.pharmaindustrial-india.com

Pint Pharma Gets ANVISA Approval of BESREMi for Polycythemia Vera

Pint Pharma and PharmaEssentia have announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow. This results in a persistent increase in red blood cells, white blood cells, and platelets. PV can lead to cardiovascular complications such as thrombosis and embolism, and in a significant number of patients it can progress to secondary myelofibrosis or leukemia. The global incidence of PV is estimated at approximately 2.8 cases per 100,000 people per year. In Brazil, between 2016 and 2020, DataSUS recorded 1,843 cases of Polycythemia Vera, representing an incidence of 0.16 per 100,000 inhabitants. Despite being a rare disease, these numbers suggest the possibility of underdiagnosis and underreporting, highlighting a challenge in identifying affected patients. According to Fernanda Bertasi, General Manager of Pint Pharma in Brazil, "ANVISA’s approval of BESREMi® represents a transformative milestone for patients with Polycythemia Vera in Brazil. This new therapeutic option brings real hope, offering innovation and progress in disease treatment. This is an essential step in providing better health and well-being for these patients." Valnei Canutti, Hematologist and Chief Scientific Officer at Pint Pharma, emphasized, "BESREMi® is an innovative, monopegylated interferon with extended action due to its unique pharmacokinetic properties. Its approval was based on robust evidence from the PEGINVERA clinical study, which demonstrated superior and more sustained hematologic and clinical responses compared to standard therapy." David Ricardo Muñoz Guzmán, CEO of Pint Pharma said, "This therapeutic advancement reaffirms Pint Pharma’s commitment to being a community-centered company. Our mission goes beyond innovation and high technology, focusing on solutions that truly impact patients' lives by expanding access to treatments and improving healthcare quality." Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia, added, "The approval of BESREMi® by ANVISA is a testament to the power of strong cross-border partnerships in advancing healthcare and reinforces our mission to transform care for PV patients worldwide. We deeply appreciate the collaboration with the Pint Pharma team, whose expertise and dedication have been instrumental in bringing BESREMi® to patients in Brazil."

Drug Approval

100 Deals associated with Ropeginterferon alfa-2b-NJFT

External Link

KEGG	Wiki	ATC	Drug Bank
D11027	Ropeginterferon alfa-2b-NJFT	L03AB15	DB15119

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Polycythemia Vera	European Union	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Iceland	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Liechtenstein	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Norway	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Myelofibrosis	Phase 3	-	PharmaEssentia Corp.	01 Dec 2024
Thrombocythemia, Essential	Phase 3	United States	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	China	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Japan	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Canada	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Hong Kong	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Singapore	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Taiwan Province	PharmaEssentia Corp.	25 Aug 2020
Chronic phase chronic myeloid leukemia	Phase 3	France	Aop Orphan Pharmaceuticals GmbH	04 May 2017
Chronic phase chronic myeloid leukemia	Phase 3	Germany	Aop Orphan Pharmaceuticals GmbH	04 May 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04285086 (EXCEED-ET, Biospace) Manual	Phase 3	Thrombocythemia, Essential Second line	174	P1101 (Ropeginterferon alfa-2b-njft)	eomgnkhddx(pjzwxjuipb) = twcoyvbrfe jzsiayotwt (roialhkzmh ) Met View more	Positive	06 Jan 2025
NCT04285086 (EXCEED-ET, Biospace) Manual	Phase 3	Thrombocythemia, Essential Second line	174	Anagrelide	eomgnkhddx(pjzwxjuipb) = frejbxwosh jzsiayotwt (roialhkzmh ) Met View more	Positive	06 Jan 2025
EHA2024 Manual	Phase 2	Polycythemia Vera JAK2V617F VAF \| IFNL4	114	Ropeginterferon alfa-2b (Ropeg)	hohsxwfgbk(zhnckobewp) = ahvyfdizuv tdumwpplyp (bgyxggyedo )	Positive	14 May 2024
EHA2024 Manual	Phase 2	Polycythemia Vera JAK2V617F VAF \| IFNL4	114	Ropeginterferon alfa-2b (Ropeg)py, STD)	hohsxwfgbk(zhnckobewp) = ituvrmoutm tdumwpplyp (bgyxggyedo )	Positive	14 May 2024
EUCTR2012-005259-18-CZ \| EUCTR2014-001357-17-PL (PROUD-PV, EHA2024) Manual	Phase 3	Polycythemia Vera JAK2V617F allele burden	169	ropeginterferon alfa-2b	wfwmilkpft(wlzldnojzk) = cumkgkikmd izkvpysofw (yqurqzbflq ) View more	Positive	14 May 2024
	Phase 3	Polycythemia Vera JAK2V617F allele burden	169	HU/BAT	wfwmilkpft(wlzldnojzk) = gaddlsdfwq izkvpysofw (yqurqzbflq ) View more	Positive	14 May 2024
EHA2024	Phase 2	Polycythemia Vera JAK2 V617F allele burden	27	Ropeginterferon alfa-2b	eyhhzbnyjr(nausnnucyq) = Although most patients (25/27 [92.6%]) experienced adverse events (AEs), ropeginterferon alfa-2b was generally well tolerated. The most common AEs were WBC count decreased (7/27 [25.9%]) and urine beta-2 microglobulin increased (6/27 [22.2%]) vmwnpoqmpw (cgtlveahmb ) View more	Positive	14 May 2024
EHA2024	Phase 3	Polycythemia Vera	34	Ropeginterferon alfa-2b	vggtdgwmbe(fuxshsjuht) = One patient developed autoimmune thyroiditis without the need to suspend treatment horhbehgxt (wgmffovzoj ) View more	Positive	14 May 2024
PROUD-PV/CONTINUATION (EHA2024)	Phase 3	Second line JAK2 mutated	12	Ropeginterferon alfa-2b	xhujvrwngx(eopdbxenxo) = One withdrew therapy due to intolerance (flushing and eczema, grade 1) after 9 months of treatment esjjkiexgm (pxxwilwuyn )	Positive	14 May 2024
ASH2023	Not Applicable	Polycythemia Vera	99	P1101	youzibpvcw(zgvemxbxfo) = abobgnnirj ouqxtodzgr (vkaapplhcs ) View more	-	11 Dec 2023
PROUD-PV/CONTINUATION-PV (ASH2023)	Not Applicable	Polycythemia Vera	-	Ropeginterferon alfa-2b	gmtwywpanu(awnnrenbct) = waafdpqdwg dufbspprpy (dzadbljvry )	-	11 Dec 2023
P1101MF (ASH2023)	Phase 2	Primary Myelofibrosis	-	Ropeginterferon alfa 2b	puzsnjyyab(hlmkurpfrc) = hwzvwsbick cppndiuhza (rvdwsgjmhv ) View more	-	11 Dec 2023
CTR20211664 \| NCT05485948 (Pubmed 1 \| Pubmed 2 \| Exp Hematol Oncol) Manual	Phase 2	Polycythemia Vera	49	ropeginterferon alfa-2b	dwprjgcbfj(hjcwrsfilm) = lmcazguwhl gdsitmaqel (ucxizigmmo ) View more	Positive	21 Jun 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis